Literature DB >> 10749111

Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells.

J L Wang1, Z J Zhang, S Choksi, S Shan, Z Lu, C M Croce, E S Alnemri, R Korngold, Z Huang.   

Abstract

Bcl-2 is a potent suppressor of apoptosis, and its overexpression contributes to tumorigenesis in many types of human cancers. To test the possibility of modulating Bcl-2 function as an anticancer strategy, a cell permeable Bcl-2 binding peptide, cell permeable moiety (cpm)-1285, was designed by chemically attaching a fatty acid to a peptide derived from the proapoptotic protein Bad. cpm-1285 entered HL-60 tumor cells, bound Bcl-2 protein, and induced apoptosis in vitro. In contrast, cpm-1285 had little effect on normal human peripheral blood lymphocytes. Furthermore, cpm-1285 had in vivo activity in slowing human myeloid leukemia growth in severe combined immunodeficient mice. These results demonstrate a novel approach for therapeutic intervention of tumor growth in vivo with small molecule inhibitors of Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749111

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Bcl-2 and apoptosis in chronic lymphocytic leukemia.

Authors:  Aaron D Schimmer; Irene Munk-Pedersen; Mark D Minden; John C Reed
Journal:  Curr Treat Options Oncol       Date:  2003-06

Review 2.  Role of Bcl-2 family proteins and caspases in the regulation of apoptosis.

Authors:  Mohammad Shamsul Ola; Mohd Nawaz; Haseeb Ahsan
Journal:  Mol Cell Biochem       Date:  2011-01-06       Impact factor: 3.396

3.  ARTS and Siah collaborate in a pathway for XIAP degradation.

Authors:  Jason B Garrison; Ricardo G Correa; Motti Gerlic; Kenneth W Yip; Andreas Krieg; Craig M Tamble; Ranxin Shi; Kate Welsh; Srinivas Duggineni; Ziwei Huang; Keqin Ren; Chunying Du; John C Reed
Journal:  Mol Cell       Date:  2010-12-23       Impact factor: 17.970

4.  Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent.

Authors:  John J Reiners; David Kessel
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

5.  Pharmacological manipulation of Bcl-2 family members to control cell death.

Authors:  Anthony Letai
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

6.  Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.

Authors:  John M Baust; Daniel P Klossner; Anthony Robilotto; Robert G Vanbuskirk; Andrew A Gage; Vladimir Mouraviev; Thomas J Polascik; John G Baust
Journal:  BJU Int       Date:  2011-08-26       Impact factor: 5.588

7.  A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing.

Authors:  Xiaoyan Yu; Hongyan Wang; Shuang Liu; Xiangming Zhang; Peter Guida; Baocheng Hu; Ya Wang
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

8.  Solution structure of the antiapoptotic protein bcl-2.

Authors:  A M Petros; A Medek; D G Nettesheim; D H Kim; H S Yoon; K Swift; E D Matayoshi; T Oltersdorf; S W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

9.  Inhibition of Siah ubiquitin ligase function.

Authors:  A Möller; C M House; C S F Wong; D B Scanlon; M C P Liu; Z Ronai; D D L Bowtell
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

10.  Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.

Authors:  Yuan Sun; Jack Wu; Amro Aboukameel; Sanjeev Banerjee; Alan A Arnold; Jianyong Chen; Zaneta Nikolovska-Coleska; Yanqiong Lin; Xiaolan Ling; Dajun Yang; Shaomeng Wang; Ayad Al-Katib; Ramzi M Mohammad
Journal:  Cancer Biol Ther       Date:  2008-09-04       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.